Medacta Group stock
MOVE.SWSIXMedacta Group S.A., HealthcareISIN CH0468525222
58Score 58 out of 100, Neutral
Price and trend
31 / 100
Price history
−29% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 20% below it.
Since May 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 37).
The price is 38% below its 52-week high. Largest decline in 8 years: 55% (April 2019 to March 2020).
Chart figures for advanced users
- SMA 50$138.46
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$163.25
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)37
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDbelow the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$127.71
- The lowest closing price of the last twelve months.
- Resistance$211.25
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Medacta Group S.A. belongs to the Medical (Specialties) industry (Switzerland) and, with a market value of $2.6B, is number 6 of 14 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $762.67M (up 16.5% year on year) and earnings of $106.51M (up 31.9%).
- MEQIRI Score 58 out of 100 (Neutral): rank 298 of 702 in Healthcare, median 53.
Show more
- The P/E is 30.2 (Healthcare sector median 26.8, own median of recent years 44.8).
- Our model puts fair value at $124.55, with the price 5% above it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Earnings per share growingUp 21.1% a year since 2020.Growth 64
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 67
- Analysts expect strong earnings growthUp 18.3% a year through 2028 (estimates from 6 analysts).Growth 64
Weaknesses
- Negative free cash flowFree cash flow −$2.05M over the last 12 months.Fundamentals 67
Its standout strengths are stability and profitability, while technical analysis and momentum hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
The fundamentals are in the middle range.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- price far below its 52-week high
- weak momentum
What lowers it
- calm price action
Valuation
Valuation signal
Fairly valuedIn our model the price counts as cheap below $95.81 and expensive above $177.92 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $133.36 (cash-flow model) and $115.74 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 7.1%. At 8.1% the fair value would be $111.69, at 6.1% it would be $144.00.
Valuation metrics
Half from the cash-flow model, half from earnings times the sector P/E (26.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Jun 2026, revenue rose 9.4% on the twelve months before. Revenue has grown strongly since 2016, at around 14% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 64%, operating 17%, net 14%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 12 Mar 2027in 119 days
- Last reported
- 9 Sep 2026EPS reported 1.94
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- 4.79−0.2%
- Revenue
- $832.11M−1.6%
- Earnings per share
- 5.73+0.1%
- Revenue
- $941M−1.4%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −4.7%2026 outlook confirmed: revenue growth of 10% to 14% and an adjusted EBITDA margin expansion of around 50 basis points, along with the midterm outlook.
“Yes, so we mentioned, at the beginning, Medacta is confirming its outlook for 2026 with revenue growth in the range of 10%-14%, and an expansion of the adjusted EBITDA margin of around 50 basis points versus prior year in constant currency.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 9 Sep 2026 (fiscal Q2 2026), read by AI.
What happened at Medacta Group
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 58
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Specialties)
The next larger and next smaller companies by market value
- STERISSTE $24.61B70
- Shanghai United Imaging Healthcare688271.SS $14.26B53
- Sysmex6869.T $7.83B71
- Ypsomed HoldingYPSN.SW $6.9B76
- Eckert & ZieglerEUZ.DE $1.01B73
- Mesa LaboratoriesMLAB $759.89M58
- QuidelOrthoQDEL $728.67M30
- Mobia MedicalMOBI $443.1M45
ETFs that hold Medacta Group
Held by 9 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.07% | 0.40% | €813.42M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.05% | 0.30% | €3.45B |
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.02% | 0.23% | €321.86M |
Show 5 more
| State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR AccZPRX | 0.01% | 0.30% | €813.64M |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.01% | 0.35% | €8.27B |
| iShares MSCI World Small Cap CTB Enhanced ESG UCITS ETFCBUG | 0.00% | 0.10% | €395.74M |
| Vanguard ESG Global All Cap UCITS ETF (USD) AccumulatingV3AA | 0.00% | 0.24% | €1.69B |
| Vanguard FTSE Global All-Cap UCITS ETF Accum USDVGLA | 0.00% | 0.07% | €3.9B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = CHF 0.8331, $1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.